CG Oncology
CG Oncology Inc is an American clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for bladder cancer. The company develops cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy designed to selectively replicate inside cancer cells and induce an anti-tumor immune response. Main revenue drivers currently stem from strategic partnership collaborations, licensing agreements, and capital financing as clinical candidate development progresses. CG Oncology targets specialized oncology markets, medical researchers, and urological cancer patients in North America and global markets. The company holds a prominent position in precision oncology innovation for non-muscle invasive bladder cancer treatments. Headquartered in Irvine, California, CG Oncology Inc is listed on the Nasdaq Stock Market.
7 of the funds FundTelligence covers report a position in CG Oncology.
- Legal name
- CG Oncology Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
Funds holding CG Oncology
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.0 % (full portfolio disclosed, September 2026)
- JPM Global Healthcare Fund — JPM · 0.67 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.53 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.43 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.21 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)